DZ3359A1 - DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS - Google Patents

DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS

Info

Publication number
DZ3359A1
DZ3359A1 DZ013359A DZ013359A DZ3359A1 DZ 3359 A1 DZ3359 A1 DZ 3359A1 DZ 013359 A DZ013359 A DZ 013359A DZ 013359 A DZ013359 A DZ 013359A DZ 3359 A1 DZ3359 A1 DZ 3359A1
Authority
DZ
Algeria
Prior art keywords
pyrrolo
pyrimidine derivatives
derivatives useful
immunosuppressant agents
immunosuppressant
Prior art date
Application number
DZ013359A
Other languages
English (en)
Inventor
Todd Andrew Blumenkopf
Mark Edward Flanagan
Michael John Munchhof
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ3359A1 publication Critical patent/DZ3359A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DZ013359A 2000-06-26 2001-06-05 DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS DZ3359A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21428700P 2000-06-26 2000-06-26
PCT/IB2001/000975 WO2002000661A1 (fr) 2000-06-26 2001-06-05 Composes pyrrolo[2,3-d]pyrimidine en tant qu'agents immunosuppresseurs

Publications (1)

Publication Number Publication Date
DZ3359A1 true DZ3359A1 (fr) 2002-01-03

Family

ID=22798508

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013359A DZ3359A1 (fr) 2000-06-26 2001-06-05 DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS

Country Status (48)

Country Link
US (4) US6696567B2 (fr)
EP (2) EP1294724B1 (fr)
JP (1) JP4068958B2 (fr)
KR (1) KR100516419B1 (fr)
CN (1) CN100351253C (fr)
AP (1) AP1911A (fr)
AR (1) AR029279A1 (fr)
AT (2) ATE423120T1 (fr)
AU (1) AU784297C (fr)
BG (1) BG107236A (fr)
BR (1) BR0111561A (fr)
CA (1) CA2412560C (fr)
CU (1) CU23263B7 (fr)
CZ (1) CZ20023993A3 (fr)
DE (2) DE60118917T2 (fr)
DK (2) DK1686130T3 (fr)
DO (1) DOP2001000200A (fr)
DZ (1) DZ3359A1 (fr)
EA (1) EA006153B1 (fr)
EC (1) ECSP014105A (fr)
EE (1) EE200200711A (fr)
ES (2) ES2318605T3 (fr)
GE (1) GEP20053541B (fr)
GT (1) GT200100117A (fr)
HR (1) HRP20021000A2 (fr)
HU (1) HUP0301114A3 (fr)
IL (2) IL152771A0 (fr)
IS (1) IS2305B (fr)
MA (1) MA26917A1 (fr)
MX (1) MXPA03000068A (fr)
MY (1) MY127236A (fr)
NO (1) NO324934B1 (fr)
NZ (1) NZ522364A (fr)
OA (1) OA12292A (fr)
PA (1) PA8521101A1 (fr)
PE (1) PE20020381A1 (fr)
PL (1) PL359563A1 (fr)
PT (1) PT1294724E (fr)
PY (1) PY0115298A (fr)
SI (1) SI1294724T1 (fr)
SK (1) SK17342002A3 (fr)
SV (1) SV2002000506A (fr)
TN (1) TNSN01095A1 (fr)
TW (1) TWI243820B (fr)
UA (1) UA74370C2 (fr)
WO (1) WO2002000661A1 (fr)
YU (1) YU83302A (fr)
ZA (1) ZA200210275B (fr)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9911365A (pt) * 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
JP4865129B2 (ja) 1999-01-13 2012-02-01 ザ・リサーチ・ファウンデーション・オブ・ステイト・ユニバーシティ・オブ・ニューヨーク タンパク質キナーゼ阻害剤を設計するための新規の方法
EP1382339B1 (fr) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions contenant des dérivés de pyrrolo¬2,3-d pyrimidine
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7129225B2 (en) * 2001-10-22 2006-10-31 The Research Foundation Of State University Of New York Protection against and treatment of hearing loss
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2445208T3 (es) 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
EP1388541A1 (fr) * 2002-08-09 2004-02-11 Centre National De La Recherche Scientifique (Cnrs) Pyrrolopyrazines utilisées comme inhibiteurs de kinases
NZ539901A (en) 2002-11-26 2007-09-28 Pfizer Prod Inc Method of treatment of transplant rejection
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300456D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
ATE556051T1 (de) * 2003-07-15 2012-05-15 Dainippon Sumitomo Pharma Co Neues heteroarylderivat
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
JP2007512316A (ja) * 2003-11-25 2007-05-17 ファイザー・プロダクツ・インク アテローム性動脈硬化症の治療方法
EP1732566A4 (fr) * 2004-04-05 2010-01-13 Takeda Pharmaceutical Compose de 6-azaindole
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
EP1768982A2 (fr) 2004-06-29 2007-04-04 Amgen Inc. Pyrrolo[2, 3-d] pyrimidines qui modulent l'activite ack1 et lck
SG155222A1 (en) * 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
AR054416A1 (es) * 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
WO2006101937A1 (fr) 2005-03-18 2006-09-28 Janssen Pharmaceutica N.V. Acylhydrazones en tant que modulateurs de kinase
KR20080025039A (ko) 2005-05-13 2008-03-19 아이알엠 엘엘씨 단백질 키나제 억제제로서의 화합물 및 조성물
WO2007046867A2 (fr) * 2005-05-19 2007-04-26 Xenon Pharmaceuticals Inc. Derives de piperidine et leurs utilisations comme agents therapeutiques
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2006133426A2 (fr) 2005-06-08 2006-12-14 Rigel Pharmaceuticals, Inc. Compositions et procedes d'inhibition de la voie jak
EP2251341A1 (fr) 2005-07-14 2010-11-17 Astellas Pharma Inc. Hétérocycles inhibiteurs de Janus kinase-3
WO2007007919A2 (fr) 2005-07-14 2007-01-18 Astellas Pharma Inc. Nouveaux composes
EP2270014A1 (fr) 2005-09-22 2011-01-05 Incyte Corporation Inhibiteurs de l'azépine de janus kinases
EP2455382B1 (fr) 2005-12-13 2016-10-26 Incyte Holdings Corporation Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines à substitution hétéroaryle en tant qu'inhibiteurs de la janus kinase
CA2642229C (fr) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions et methodes destinees a l'inhibition de la voie jak
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
WO2008029237A2 (fr) * 2006-09-05 2008-03-13 Pfizer Products Inc. Polythérapies destinées au traitement de l'arthrite rhumatoïde
WO2008063888A2 (fr) 2006-11-22 2008-05-29 Plexxikon, Inc. Composés modulant l'activité de c-fms et/ou de c-kit et utilisations associées
EP2121692B1 (fr) 2006-12-22 2013-04-10 Incyte Corporation Hétérocycles substitués servant d'inhibiteurs de janus kinases
EP2123651A4 (fr) 2007-01-12 2011-05-04 Astellas Pharma Inc Composé de pyridine condensée
EP3070090B1 (fr) 2007-06-13 2018-12-12 Incyte Holdings Corporation Utilisation des sels de l'inhibiteur de janus kinase (r)-3-(4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl) -3-cyclopentylpropanenitrile
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
PL2201012T3 (pl) 2007-10-11 2014-11-28 Astrazeneca Ab Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinazy białkowej b
US8309566B2 (en) 2008-02-15 2012-11-13 Rigel Pharmaceuticals, Inc. Pyrimidine-2-amine compounds and their use as inhibitors of JAK kinases
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
MX2010011463A (es) 2008-04-16 2011-06-03 Portola Pharm Inc 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas.
NZ588830A (en) 2008-04-22 2012-11-30 Portola Pharm Inc Inhibitors of protein kinases
US20110165183A1 (en) * 2008-08-01 2011-07-07 Biocryst Pharmaceuticals, Inc. Piperidine derivatives as jak3 inhibitors
JP4884570B2 (ja) * 2008-08-20 2012-02-29 ファイザー・インク ピロロ［２，３−ｄ］ピリミジン化合物
US8385364B2 (en) * 2008-09-24 2013-02-26 Nec Laboratories America, Inc. Distributed message-passing based resource allocation in wireless systems
CA2752150A1 (fr) * 2009-02-11 2010-08-19 Reaction Biology Corp. Inhibiteurs de kinase selectifs
KR101739994B1 (ko) 2009-04-03 2017-05-25 에프. 호프만-라 로슈 아게 프로판-１-술폰산 ｛３-［５-（４-클로로-페닐）-１Ｈ-피롤로［２，３-ｂ］피리딘-３-카르보닐］-２，４-디플루오로-페닐｝-아미드 조성물 및 그의 용도
EP2421867B1 (fr) 2009-04-20 2015-09-02 Auspex Pharmaceuticals, Llc Inhibiteurs pipéridiniques de la janus kinase 3
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
TW201111385A (en) * 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
PT2473049T (pt) 2009-09-04 2019-03-04 Sunesis Pharmaceuticals Inc Inibidores de tirosina quinase de bruton
US9029359B2 (en) 2009-09-04 2015-05-12 Biogen Idec Ma, Inc. Heteroaryl Btk inhibitors
KR101921850B1 (ko) 2009-10-09 2018-11-23 인사이트 홀딩스 코포레이션 3-（4-（7Ｈ-피롤로〔2,3-ｄ〕피리미딘-4-일）-1Ｈ-피라졸-1-일）-3-사이클로펜틸프로판니트릴의 하이드록실, 케토 및 글루쿠로나이드 유도체
CA2776028C (fr) * 2009-10-15 2015-12-01 Pfizer Inc. Composes pyrrolo[2,3-d]pyrimidine
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
ES2461967T3 (es) * 2009-12-18 2014-05-21 Pfizer Inc. Compuestos de pirrolo[2,3-d]pirimidina
JP2013518882A (ja) * 2010-02-05 2013-05-23 ファイザー・インク ＪＡＫ阻害剤としてのピロロ［２，３−ｄ］ピリミジン尿素化合物
CN102781431B (zh) * 2010-02-24 2014-08-27 硕腾有限责任公司 兽医组合物
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
TWI619713B (zh) * 2010-04-21 2018-04-01 普雷辛肯公司 用於激酶調節的化合物和方法及其適應症
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
EP2606051B1 (fr) 2010-08-20 2016-10-05 Hutchison Medipharma Limited Composés de pyrrolopyrimidine et leurs utilisations
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
US9102625B2 (en) 2010-11-01 2015-08-11 Portola Pharmaceuticals, Inc. Nicotinamides as JAK kinase modulators
WO2012068440A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Pyrrolopyridines et pyrrolopyrimidines à substitution hétérocyclique utilisées en tant qu'inhibiteurs des jak
CA2818542A1 (fr) 2010-11-19 2012-05-24 Incyte Corporation Derives pyrrolopyridine et pyrrolopyrimidine a substitution cyclobutyle utilises comme inhibiteurs des jak
KR101911972B1 (ko) 2011-02-07 2018-10-25 플렉시콘 인코퍼레이티드 키나제 조절을 위한 화합물 및 방법, 및 그에 대한 적응증
CA2827673C (fr) 2011-02-18 2020-10-27 Novartis Pharma Ag Pluritherapie impliquant un inhibiteur de mtor et un inhibiteur de jak
WO2012127506A1 (fr) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Composés tricycliques substitués; compositions et applications médicinales correspondantes
EP2694056B1 (fr) 2011-04-01 2019-10-16 AstraZeneca AB Traitement thérapeutique
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2741747A1 (fr) 2011-08-10 2014-06-18 Novartis Pharma AG Polythérapie par jak p13k/mtor
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
CA3094793A1 (fr) 2011-11-23 2013-05-30 Portola Pharmaceuticals, Inc. Inhibiteurs de de la pyrazine kinase
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
EP4556010A3 (fr) 2011-11-30 2025-07-23 Emory University Inhibiteurs jak destinées à la prévention ou au traitement d'une maladie causé par une coronaviridée
KR102032934B1 (ko) * 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
AU2013239816B2 (en) 2012-03-29 2017-08-24 G1 Therapeutics, Inc. Lactam kinase inhibitors
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
AR091273A1 (es) 2012-06-08 2015-01-21 Biogen Idec Inc Inhibidores de pirimidinil tirosina quinasa
IN2015DN02008A (fr) 2012-09-21 2015-08-14 Advinus Therapeutics Ltd
US9676756B2 (en) 2012-10-08 2017-06-13 Portola Pharmaceuticals, Inc. Substituted pyrimidinyl kinase inhibitors
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
US9481679B2 (en) 2012-12-17 2016-11-01 Sun Pharmaceutical Industries Limited Process for the preparation of tofacitinib and intermediates thereof
CU24275B1 (es) 2013-02-22 2017-10-05 Pfizer Derivados de cicloalquilo pirrolo [2,3-d] pirimidina-4-il amino útiles como inhibidores de quinasas janus relacionadas y composiciones farmacéuticas que contienen tales compuestos
WO2014138168A1 (fr) 2013-03-06 2014-09-12 Incyte Corporation Procédés et intermédiaires pour la génération d'un inhibiteur de jak
HK1222766A1 (zh) 2013-03-15 2017-07-14 G1治疗公司 高效的抗赘生剂和抗增生剂
DK2968290T3 (da) 2013-03-15 2019-11-25 G1 Therapeutics Inc Transient beskyttelse af normale celler under kemoterapi
EP3006445B1 (fr) * 2013-06-07 2017-11-15 Jiangsu Hengrui Medicine Co. Ltd. Hydrogénosulfate d'inhibiteur de janus kinase (jak) et son procédé de préparation
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
KR102325163B1 (ko) * 2013-08-22 2021-11-11 제넨테크, 인크. 화합물의 제조 방법
WO2015027090A1 (fr) * 2013-08-22 2015-02-26 Genentech, Inc. Intermédiaires et procédés pour la préparation de composés
MX368464B (es) * 2013-12-05 2019-10-02 Pfizer Acrilamidas de pirrolo[2,3-d]pirimidinilo, pirrolo[2,3-b]pirazinil o y pirrolo[2,3-d]piridinilo.
WO2015161285A1 (fr) 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Lactames tricycliques utilisables dans la protection de cellules souches et progénitrices hématopoïétiques contre le rayonnement ionisant
ES2842592T3 (es) * 2014-05-19 2021-07-14 Boehringer Ingelheim Animal Health Usa Inc Compuestos antihelmínticos
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3180344B1 (fr) 2014-08-12 2019-09-18 Pfizer Inc Dérivés de pyrrolo[2,3-d]pyrimidine utiles pour inhiber la janus kinase
KR101710127B1 (ko) * 2014-08-29 2017-02-27 한화제약주식회사 야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
WO2016040858A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinaisons et régimes posologiques pour traiter des tumeurs rb-positives
WO2016040848A1 (fr) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Traitement de tumeurs rb-négatives en utilisant des inhibiteurs de la topoisomérase en association avec des inhibiteurs des kinases cycline-dépendantes 4/6
CN105566327A (zh) * 2014-10-09 2016-05-11 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法
CN105980390B (zh) * 2014-11-05 2017-07-07 江苏恒瑞医药股份有限公司 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法
EP3248980B1 (fr) * 2015-01-20 2023-09-06 Wuxi Fortune Pharmaceutical Co., Ltd Inhibiteur de jak
US10703756B2 (en) 2015-05-01 2020-07-07 Pfizer Inc. Pyrrolo[2,3-D]pyrimidinyl, pyrrolo[2,3-B]pyrazinyl, pyrrolo[2,3-B]pyridinyl acrylamides and epoxides thereof
KR101771219B1 (ko) * 2015-08-21 2017-09-05 양지화학 주식회사 야누스 키나제 1 선택적 억제제 및 그 의약 용도
CN108472298B (zh) 2015-11-24 2021-04-20 深圳阿拉丁医疗科技有限公司 选择性激酶抑制剂
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
WO2018005863A1 (fr) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Composés à base de pyrimidine pour le traitement du cancer
JP7214632B2 (ja) 2016-07-21 2023-01-30 バイオジェン エムエー インク． ブルトン型チロシンキナーゼ阻害剤のコハク酸塩形態および組成物
CN106120090A (zh) * 2016-08-31 2016-11-16 飞佛特种纺织品（宁波）有限公司 一种防刮擦阳光面料的制备方法
MX391179B (es) * 2016-11-23 2025-03-21 Jiangsu Hengrui Medicine Co Método de preparación e intermediario de derivado de un anillo heteroaromático de seis miembros pirrolo
EP3565558B1 (fr) 2017-01-06 2023-12-06 G1 Therapeutics, Inc. Polythérapie avec un composé serd et un inhibiteur cdk4/6 pour le traitement du cancer
CN106831538B (zh) * 2017-01-22 2019-06-25 苏州楚凯药业有限公司 托法替尼中间体的制备方法
WO2018154133A1 (fr) * 2017-02-27 2018-08-30 Janssen Pharmaceutica Nv Dérivés de [1,2,4]-triazolo [1,5-a]-pyrimidinyle substitués par de la pipéridine, de la morpholine ou de la pipérazine utilisés en tant qu'inhibiteurs d'oga
CN107337676A (zh) * 2017-06-08 2017-11-10 江苏正大清江制药有限公司 一种托法替布起始原料的制备方法
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
RS67557B1 (sr) 2018-08-24 2026-01-30 Pharmacosmos Holding As Unapređena sinteza 1,4-diazaspiro[5.5]undekan-3-ona
NL2022471B1 (en) 2019-01-29 2020-08-18 Vationpharma B V Solid state forms of oclacitinib
WO2020198583A1 (fr) 2019-03-27 2020-10-01 Insilico Medicine Ip Limited Inhibiteurs de jak bicycliques et leurs utilisations
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021009568A1 (fr) 2019-07-17 2021-01-21 2692372 Ontario, Inc. Dérivés de benzènesulfonamide et leurs utilisations
CN115038443A (zh) 2019-11-22 2022-09-09 因西特公司 包含alk2抑制剂和jak2抑制剂的组合疗法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
WO2022117075A1 (fr) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 Composé azacyclique, son procédé de préparation et son utilisation
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3670079A (en) * 1970-10-06 1972-06-13 Merck & Co Inc Anabolic agents
US4997936A (en) * 1977-10-19 1991-03-05 Merck & Co., Inc. 2-carbamimidoyl-6-substituted-1-carbadethiapen-2-em-3-carboxylic acids
US4456464A (en) * 1982-05-19 1984-06-26 Zoecon Corporation Phenoxy- and pyridyloxy-phenoxyalkyl phosphinates and related sulfur compounds for weed control
US4526608A (en) * 1982-07-14 1985-07-02 Zoecon Corporation Certain 2-pyridyloxyphenyl-oximino-ether-carboxylates, herbicidal compositions containing same and their herbicidal method of use
US4590282A (en) * 1984-09-24 1986-05-20 Sandoz Ltd. Pest control agents
US4933339A (en) * 1985-08-21 1990-06-12 Rohm And Haas Company (2-cyano-2-arylethyl)pyridine compounds useful in controlling fungicidal activity
CA1328333C (fr) * 1988-03-04 1994-04-05 Quirico Branca Derives d'acide amine
US4879309A (en) * 1988-09-27 1989-11-07 Schering Corporation Mercapto-acylamino acids as antihypertensives
US5356903A (en) * 1993-04-22 1994-10-18 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolines
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5389509A (en) 1993-10-04 1995-02-14 Eastman Kodak Company Ultrathin high chloride tabular grain emulsions
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
EP0682027B1 (fr) 1994-05-03 1997-10-15 Novartis AG Dérivés de la pyrrolopyrimidine avec une activité anti-proliférative
ATE247469T1 (de) 1995-06-07 2003-09-15 Pfizer Heterocyclische kondensierte pyrimidin-derivate
BR9609613A (pt) 1995-07-05 1999-05-25 Du Pont Composto composição fungicida e método de controle de doenças de plantas
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
ATE201873T1 (de) 1995-11-14 2001-06-15 Pharmacia & Upjohn Spa Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate
ATE217873T1 (de) 1996-01-23 2002-06-15 Novartis Erfind Verwalt Gmbh Pyrrolopyrimidinen und verfahren zu deren herstellung
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
GB9604361D0 (en) * 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU1794697A (en) 1996-03-06 1997-09-22 Novartis Ag 7-alkyl-pyrrolo{2,3-d}pyrimidines
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
WO1998007726A1 (fr) 1996-08-23 1998-02-26 Novartis Ag Pyrrolopyrimidines substituees et procede pour leur preparation
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
ES2301194T3 (es) 1997-02-05 2008-06-16 Warner-Lambert Company Llc Pirido 2,3-d pirimidinas y 4-aminopirimidinas como inhibidores de la proliferacion celular.
WO1998043087A1 (fr) 1997-03-24 1998-10-01 Pharmacia & Upjohn Company Procede d'identification d'inhibiteurs de la liaison proteine jak2/recepteur de cytokine
JP2002510687A (ja) 1998-04-02 2002-04-09 ニューロゲン コーポレイション アミノアルキル置換ピロロ［２，３−ｂ］ピリジンおよびピロロ［２，３−ｄ］ピリミジン誘導体：ｃｒｆ１レセプタのモジュレータ
WO1999061428A1 (fr) 1998-05-28 1999-12-02 Parker Hughes Institute Utilisation des quinazolines pour le traitement de tumeurs cerebrales
BR9911365A (pt) * 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
WO2000000202A1 (fr) 1998-06-30 2000-01-06 Parker Hughes Institute Procede pour inhiber l'expression de c-jun en utilisant les inhibiteurs de jak-3
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
CA2344249A1 (fr) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines utilisees comme inhibiteurs de proteines kinases
CZ27399A3 (cs) * 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
IL148903A0 (en) * 1999-09-30 2002-09-12 Neurogen Corp Certain alkylene diamine-substituted heterocycles
EP1382339B1 (fr) * 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions contenant des dérivés de pyrrolo¬2,3-d pyrimidine
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7253166B2 (en) * 2003-04-22 2007-08-07 Irm Llc 6-phenyl-7H-pyrrolo[2,3-d]pyrimidine compounds that induce neuronal differentiation in embryonic stem cells
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo

Also Published As

Publication number Publication date
AP1911A (en) 2008-10-30
CZ20023993A3 (cs) 2004-02-18
JP4068958B2 (ja) 2008-03-26
DK1686130T3 (da) 2009-04-06
MA26917A1 (fr) 2004-12-20
AU784297B2 (en) 2006-03-02
OA12292A (en) 2003-11-11
US20070161666A1 (en) 2007-07-12
ES2257410T3 (es) 2006-08-01
DE60118917D1 (de) 2006-05-24
IS6606A (is) 2002-10-31
SK17342002A3 (sk) 2004-06-08
ATE323704T1 (de) 2006-05-15
ECSP014105A (es) 2002-01-25
UA74370C2 (uk) 2005-12-15
GEP20053541B (en) 2005-06-10
IL152771A0 (en) 2003-06-24
TNSN01095A1 (fr) 2005-11-10
GT200100117A (es) 2002-01-31
CN100351253C (zh) 2007-11-28
BR0111561A (pt) 2003-09-09
EP1686130A1 (fr) 2006-08-02
KR20030017561A (ko) 2003-03-03
NO20026030L (no) 2002-12-16
AR029279A1 (es) 2003-06-18
EP1686130B1 (fr) 2009-02-18
US20050197349A1 (en) 2005-09-08
WO2002000661A1 (fr) 2002-01-03
CA2412560A1 (fr) 2002-01-03
ZA200210275B (en) 2003-12-19
IS2305B (is) 2007-10-15
NO20026030D0 (no) 2002-12-16
PY0115298A (es) 2003-11-03
AU784297C (en) 2007-01-11
NZ522364A (en) 2004-09-24
EP1294724A1 (fr) 2003-03-26
US7192963B2 (en) 2007-03-20
ATE423120T1 (de) 2009-03-15
US6962993B2 (en) 2005-11-08
PA8521101A1 (es) 2002-04-25
KR100516419B1 (ko) 2005-09-23
HUP0301114A2 (hu) 2003-08-28
TWI243820B (en) 2005-11-21
SI1294724T1 (sl) 2006-08-31
AP2002002695A0 (en) 2002-12-31
DE60118917T2 (de) 2006-11-30
EP1294724B1 (fr) 2006-04-19
HK1054930A1 (en) 2003-12-19
EA200201096A1 (ru) 2003-04-24
NO324934B1 (no) 2008-01-07
IL152771A (en) 2009-06-15
CA2412560C (fr) 2008-12-30
US20020068746A1 (en) 2002-06-06
JP2004501922A (ja) 2004-01-22
DE60137734D1 (de) 2009-04-02
BG107236A (bg) 2003-09-30
ES2318605T3 (es) 2009-05-01
DK1294724T3 (da) 2006-07-17
YU83302A (sh) 2005-09-19
AU6053801A (en) 2002-01-08
EE200200711A (et) 2004-06-15
HUP0301114A3 (en) 2004-11-29
EA006153B1 (ru) 2005-10-27
CU23263B7 (es) 2008-03-14
HRP20021000A2 (en) 2005-02-28
CN1439010A (zh) 2003-08-27
US20030220353A1 (en) 2003-11-27
MY127236A (en) 2006-11-30
PL359563A1 (pl) 2004-08-23
DOP2001000200A (es) 2003-02-15
SV2002000506A (es) 2002-10-24
MXPA03000068A (es) 2003-09-25
PT1294724E (pt) 2006-07-31
PE20020381A1 (es) 2002-05-13
US6696567B2 (en) 2004-02-24

Similar Documents

Publication Publication Date Title
DZ3359A1 (fr) DÉRIVÉS DE PYRROLO [2,3-d] PYRIMIDINE UTILES COMME AGENTS IMMUNOSUPPRESSEURS
MA26851A1 (fr) Derives de pyrrolo [2,3-d] pyrimidine
MA26825A1 (fr) Derives de pyrazolo [4,3-d] pyrimidine
DK1087971T3 (da) Pyrrolo[2,3-d]pyrimidinforbindelser
IS6288A (is) 5-(2-setnin-5-heterósýklýlsúlfónýlpýrid-3-ýl)díhýdrópýrazóló[4,3-d]pýrimidín-7-ón sem fosfódíesterasa latar
DK0996621T3 (da) Triazolo[4,5-d]pyrimidin-derivater som anti-trombotiske midler
DE69915675D1 (de) Triazolo[4,5-d]pyrimidin-derivate
DK1087970T3 (da) Pyrrol[2,3-d]pyrimidin forbindelser
DE60103909D1 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
NO20020931D0 (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
DE50001191D1 (de) Pyrazolo[4, 3-d]pyrimidine
PL363077A1 (en) Use of pyrazolo[4,3-d]pyrimidines
PL361890A1 (en) Use of pyrazolo[4,3-d]pyrimidines
SI0996621T1 (en) TRIAZOLO(4,5-d)PYRIMIDINE DERIVATIVES AS ANTI-THROMBOTIC AGENTS
HK1068632A (en) Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents